Avestar Capital LLC acquired a new position in Eli Lilly and Co (NYSE:LLY) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,225 shares of the company’s stock, valued at approximately $100,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Ellington Management Group LLC acquired a new stake in shares of Eli Lilly and during the fourth quarter worth $701,000. HPM Partners LLC raised its position in shares of Eli Lilly and by 71.9% during the fourth quarter. HPM Partners LLC now owns 11,298 shares of the company’s stock worth $954,000 after purchasing an additional 4,726 shares during the period. Stone Ridge Asset Management LLC acquired a new stake in shares of Eli Lilly and during the fourth quarter worth $2,226,000. Cornercap Investment Counsel Inc. raised its position in shares of Eli Lilly and by 27.3% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 44,386 shares of the company’s stock worth $3,748,000 after purchasing an additional 9,515 shares during the period. Finally, Guggenheim Capital LLC raised its position in shares of Eli Lilly and by 21.5% during the fourth quarter. Guggenheim Capital LLC now owns 701,899 shares of the company’s stock worth $59,283,000 after purchasing an additional 124,217 shares during the period. 77.58% of the stock is currently owned by institutional investors.
Eli Lilly and Co (NYSE LLY) opened at $79.15 on Wednesday. Eli Lilly and Co has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $86,720.00, a price-to-earnings ratio of 48.86, a PEG ratio of 1.48 and a beta of 0.28.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $76.50, for a total value of $65,790.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the transaction, the senior vice president now owns 152,120 shares in the company, valued at approximately $12,339,974.40. The disclosure for this sale can be found here. Insiders sold 12,261 shares of company stock worth $987,485 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.
A number of brokerages have recently issued reports on LLY. TheStreet lowered Eli Lilly and from a “b” rating to a “c” rating in a research report on Monday, March 5th. Jefferies Group set a $93.00 target price on Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. JPMorgan Chase & Co. set a $105.00 target price on Eli Lilly and and gave the stock a “buy” rating in a research report on Monday, February 26th. Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 target price on shares of Eli Lilly and in a research report on Friday, February 2nd. Finally, Bank of America cut their target price on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 1st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $93.47.
WARNING: This news story was posted by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.themarketsdaily.com/2018/03/14/1225-shares-in-eli-lilly-and-co-lly-purchased-by-avestar-capital-llc.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.